Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to FSH receptors on ovarian granulosa cells, stimulating estrogen production and follicle growth. The LH component binds to LH receptors on theca cells, promoting androgen conversion to estrogen and triggering final follicular maturation and ovulation. Together they mimic the natural hormonal surge required for oocyte development.

The dose of Meriofert is individualized and set by the prescribing physician based on the patient’s ovarian response, body weight, and treatment protocol. The prescriber determines the amount, frequency, and duration of administration to achieve the desired ovarian stimulation while minimizing risk.

Meriofert is intended for use before conception to stimulate ovulation and is not recommended during pregnancy. Safety data for use while breastfeeding are limited; therefore, it should be avoided unless the benefits outweigh potential risks and a healthcare professional advises otherwise.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Meriofert combines both FSH and LH in a single injectable formulation, offering a convenient alternative to using separate FSH‑only and LH‑only preparations. This dual‑action approach can simplify dosing schedules and may improve synchronization of follicular development compared with single‑component gonadotropins.

Meriofert must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Meriofert is administered by a healthcare professional via intramuscular or subcutaneous injection, typically in the thigh or abdomen. The exact injection site, volume, and frequency are determined by the treating physician based on the individual treatment plan.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can lead to fluid accumulation, thrombosis, or organ dysfunction, and the possibility of multiple pregnancy. Prompt monitoring and dose adjustment are essential to mitigate these risks.

Meriofert is contraindicated in women who are currently pregnant, have uncontrolled thyroid disease, estrogen‑sensitive tumors, or a history of severe OHSS. It should also be avoided in patients with known hypersensitivity to any component of the formulation.